ES2294313T3 - Derivados de piridina como moduladores del receptor cb2. - Google Patents
Derivados de piridina como moduladores del receptor cb2. Download PDFInfo
- Publication number
- ES2294313T3 ES2294313T3 ES03750676T ES03750676T ES2294313T3 ES 2294313 T3 ES2294313 T3 ES 2294313T3 ES 03750676 T ES03750676 T ES 03750676T ES 03750676 T ES03750676 T ES 03750676T ES 2294313 T3 ES2294313 T3 ES 2294313T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- halogen
- group
- substituted
- nr8ar8b
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0222493.9A GB0222493D0 (en) | 2002-09-27 | 2002-09-27 | Compounds |
| GB0222493 | 2002-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2294313T3 true ES2294313T3 (es) | 2008-04-01 |
Family
ID=9944904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03750676T Expired - Lifetime ES2294313T3 (es) | 2002-09-27 | 2003-09-25 | Derivados de piridina como moduladores del receptor cb2. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20060240048A1 (enExample) |
| EP (1) | EP1565442B1 (enExample) |
| JP (1) | JP2006503845A (enExample) |
| KR (1) | KR20050071514A (enExample) |
| CN (1) | CN1703402A (enExample) |
| AR (1) | AR041395A1 (enExample) |
| AT (1) | ATE378317T1 (enExample) |
| AU (1) | AU2003268907A1 (enExample) |
| BR (1) | BR0314635A (enExample) |
| CA (1) | CA2500231A1 (enExample) |
| DE (1) | DE60317555T2 (enExample) |
| ES (1) | ES2294313T3 (enExample) |
| GB (1) | GB0222493D0 (enExample) |
| IS (1) | IS7809A (enExample) |
| MA (1) | MA27448A1 (enExample) |
| MX (1) | MXPA05003263A (enExample) |
| NO (1) | NO20052028L (enExample) |
| NZ (1) | NZ538943A (enExample) |
| PL (1) | PL375990A1 (enExample) |
| RU (1) | RU2005112752A (enExample) |
| TW (1) | TW200413321A (enExample) |
| WO (1) | WO2004029026A1 (enExample) |
| ZA (1) | ZA200502084B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003082191A2 (en) | 2002-03-28 | 2003-10-09 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
| UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| GB0402355D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| GB0402356D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| GB0402357D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| SE0401342D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
| SE0401345D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine as scaffold |
| SE0401343D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine N oxide as scaffold |
| ATE412651T1 (de) | 2004-06-09 | 2008-11-15 | Glaxo Group Ltd | Pyrrolopyridinderivate |
| EA200800562A1 (ru) * | 2005-08-09 | 2008-06-30 | Глаксо Груп Лимитед | Производные имидазопиридина в качестве лигандов каннабиноидного рецептора |
| GB0519760D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
| CA2643863A1 (en) * | 2006-04-07 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| AU2007304363B2 (en) | 2006-10-04 | 2013-01-17 | F. Hoffmann-La Roche Ag | Pyrazine-2-carboxamide derivatives as CB2 receptor modulators |
| WO2008063625A2 (en) * | 2006-11-20 | 2008-05-29 | Adolor Corporation | Pyridine compounds and methods of their use |
| MX2009009035A (es) * | 2007-02-22 | 2009-12-14 | Hemerus Medical Llc | Aparato de alta capacidad para filtracion de fluidos biologicos. |
| KR20110117146A (ko) * | 2009-01-22 | 2011-10-26 | 라퀄리아 파마 인코포레이티드 | Ｃｂ2 수용체 효능활성이 있는 ｎ-치환 포화 헤테로사이클릭 술폰 화합물 |
| EP2415765A4 (en) | 2009-03-30 | 2012-08-15 | Astellas Pharma Inc | PYRIMIDINE COMPOUND |
| CN105693601A (zh) * | 2009-08-24 | 2016-06-22 | 纽若斯丹公司 | 神经刺激性哌嗪的合成 |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| JP2013048962A (ja) * | 2012-12-12 | 2013-03-14 | Hemerus Medical Llc | 大容量の体液濾過装置 |
| WO2018055640A1 (en) * | 2016-09-22 | 2018-03-29 | Srf Limited | Process for the preparation of haloalkyl derivatives of nicotinic acid |
| SG11202009103WA (en) * | 2018-06-27 | 2020-10-29 | Hoffmann La Roche | Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| CN112119068A (zh) | 2018-06-27 | 2020-12-22 | 豪夫迈·罗氏有限公司 | 作为大麻素受体2的抑制剂的新型氮杂环丁烷-取代的吡啶和吡嗪化合物 |
| CN112638430B (zh) | 2018-06-27 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
| WO2020025574A1 (en) | 2018-08-03 | 2020-02-06 | Bayer Aktiengesellschaft | Process for the preparation of 6-(haloalkyl)-2-halo-5-acylpyridines and intermediates for this process |
| EP3666759A1 (en) | 2018-12-10 | 2020-06-17 | Bayer Aktiengesellschaft | Preparation of 6-halo-2-(haloalkyl)-3-acylpyridines and intermediates therefor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
-
2002
- 2002-09-27 GB GBGB0222493.9A patent/GB0222493D0/en not_active Ceased
-
2003
- 2003-09-25 CA CA002500231A patent/CA2500231A1/en not_active Abandoned
- 2003-09-25 EP EP03750676A patent/EP1565442B1/en not_active Expired - Lifetime
- 2003-09-25 JP JP2004539056A patent/JP2006503845A/ja not_active Withdrawn
- 2003-09-25 RU RU2005112752/04A patent/RU2005112752A/ru not_active Application Discontinuation
- 2003-09-25 PL PL03375990A patent/PL375990A1/xx not_active Application Discontinuation
- 2003-09-25 BR BR0314635-9A patent/BR0314635A/pt not_active IP Right Cessation
- 2003-09-25 DE DE60317555T patent/DE60317555T2/de not_active Expired - Fee Related
- 2003-09-25 AT AT03750676T patent/ATE378317T1/de not_active IP Right Cessation
- 2003-09-25 NZ NZ538943A patent/NZ538943A/en unknown
- 2003-09-25 US US10/528,613 patent/US20060240048A1/en not_active Abandoned
- 2003-09-25 KR KR1020057005234A patent/KR20050071514A/ko not_active Withdrawn
- 2003-09-25 CN CNA038254727A patent/CN1703402A/zh active Pending
- 2003-09-25 WO PCT/EP2003/010930 patent/WO2004029026A1/en not_active Ceased
- 2003-09-25 AR ARP030103499A patent/AR041395A1/es not_active Application Discontinuation
- 2003-09-25 AU AU2003268907A patent/AU2003268907A1/en not_active Abandoned
- 2003-09-25 TW TW092126422A patent/TW200413321A/zh unknown
- 2003-09-25 MX MXPA05003263A patent/MXPA05003263A/es unknown
- 2003-09-25 ES ES03750676T patent/ES2294313T3/es not_active Expired - Lifetime
-
2005
- 2005-03-11 ZA ZA200502084A patent/ZA200502084B/en unknown
- 2005-03-28 MA MA28176A patent/MA27448A1/fr unknown
- 2005-04-19 IS IS7809A patent/IS7809A/is unknown
- 2005-04-26 NO NO20052028A patent/NO20052028L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200413321A (en) | 2004-08-01 |
| CA2500231A1 (en) | 2004-04-08 |
| EP1565442B1 (en) | 2007-11-14 |
| KR20050071514A (ko) | 2005-07-07 |
| DE60317555T2 (de) | 2008-10-23 |
| NZ538943A (en) | 2007-01-26 |
| RU2005112752A (ru) | 2006-01-20 |
| JP2006503845A (ja) | 2006-02-02 |
| BR0314635A (pt) | 2005-08-02 |
| IS7809A (is) | 2005-04-19 |
| GB0222493D0 (en) | 2002-11-06 |
| PL375990A1 (en) | 2005-12-12 |
| DE60317555D1 (de) | 2007-12-27 |
| ATE378317T1 (de) | 2007-11-15 |
| US20060240048A1 (en) | 2006-10-26 |
| WO2004029026A1 (en) | 2004-04-08 |
| MA27448A1 (fr) | 2005-07-01 |
| NO20052028L (no) | 2005-06-03 |
| AR041395A1 (es) | 2005-05-18 |
| MXPA05003263A (es) | 2005-07-05 |
| CN1703402A (zh) | 2005-11-30 |
| ZA200502084B (en) | 2006-02-22 |
| AU2003268907A1 (en) | 2004-04-19 |
| EP1565442A1 (en) | 2005-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2294313T3 (es) | Derivados de piridina como moduladores del receptor cb2. | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| CO5700754A2 (es) | Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas | |
| AR105340A2 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden | |
| BR0208455A (pt) | Derivados de glutaramida substituìda com n-fenpropilciclopentila como inibidores de nep para a fsad | |
| AR109958A1 (es) | Lactamas bicíclicas de piridona y sus métodos de uso | |
| BRPI0414592A (pt) | antagonistas de receptores de trombina | |
| CO6190512A2 (es) | Compuestos antagonistas del receptor de glucagon composiciones que contienen dichos compuestos y procedimientos de uso | |
| ES2271615T3 (es) | N-aril-2-oxazolidinona-5-carboxamidas y sus derivados y su uso como antibacterianos. | |
| ATE506354T1 (de) | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren | |
| ATE429427T1 (de) | Pyrimidinderivate als orexin-rezeptorantagonisten | |
| AR058776A1 (es) | Compuesto de piridina condensado | |
| NO20070288L (no) | Nye alkynylderivater som modulatorer av metabotropiske glutamatreseptorer | |
| PE20160431A1 (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica | |
| AR066946A1 (es) | Compuestos heterociclicos antagonistas del receptor de histamina h3, y sus usos terapeuticos | |
| AR076900A1 (es) | Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc | |
| CO6190521A2 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta -9 desaturasa | |
| AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
| AR054369A1 (es) | Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| HRP20080227T3 (hr) | Pirolidinski derivati kao ligandi histaminskih receptora | |
| IN2012DN03449A (enExample) |